Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02153151 · ClinicalTrials.gov registry record
Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy
A clinical trial, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- 21
- Enrollment target
NCT02153151 is a clinical trial that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 21 participants.
The verdict
NCT02153151 has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
Study Summary
This pilot research trial studies the response in blood cells to AMP-514, a drug shown to increase immune response (capacity to fight against infections and cancer) against cancer in patients with solid tumors undergoing radiotherapy. Measuring changes in biomarkers may help doctors decide if AMP-514 should be combined with radiotherapy and when is the best time to combine the drug with radiation.
Interventions
- OTHER Laboratory biomarker analysis
- OTHER Cytology specimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2013-11-11 |
| Est. Completion | 2016-07-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02153151
The ClinicalTrials.gov registry entry for NCT02153151 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory biomarker analysis is the first listed.
NCT02153151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02153151 about?
NCT02153151 is a clinical study titled "Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy". This pilot research trial studies the response in blood cells to AMP-514, a drug shown to increase immune response (capacity to fight against infections and cancer) against cancer in patients with solid tumors undergoing radiotherapy. Measuring changes in biomarkers may help doctors decide if AMP-51...
What is the current status of trial NCT02153151?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2013-11-11. Estimated completion is 2016-07-14.
What interventions are being tested in trial NCT02153151?
The interventions under investigation include: Laboratory biomarker analysis (OTHER), Cytology specimen (OTHER).
Who is sponsoring clinical trial NCT02153151?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.